Moderna Looks to Pare R&D Spending Even as It Pivots From Covid Vaccines.
- Resource Type
- Article
- Authors
- Maurer, Mark
- Source
- Wall Street Journal - Online Edition. 3/7/2024, pN.PAG-N.PAG. 1p.
- Subject
- *COVID-19 vaccines
*CASH & cash equivalents
*COMBINED vaccines
- Language
Moderna, a biotech company known for its Covid-19 vaccine, is looking to reduce its research and development (R&D) spending while diversifying its commercial drug sales. The company plans to cut costs and bring more drugs to market as its Covid-19 vaccine sales decline. Moderna aims to balance speed and cost in the next three years, unlike during the pandemic when it moved quickly. The company expects to reduce R&D expenses by 7% this year and has 45 programs in its pipeline. Moderna is also focused on improving efficiency in manufacturing and exploring ways to boost productivity. [Extracted from the article]